TAS-103. Antineoplastic topoisomerase I and II inhibitor

Drugs of the Future

Volumn 23, Issue 5, 1998, Pages 513-515

  Hoshi, A ^a   Castaner J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; IRINOTECAN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALOPECIA; ANIMAL CELL; BONE MARROW SUPPRESSION; CANCER CELL; CLINICAL TRIAL; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER TOXICITY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SOLID TUMOR; STOMACH CARCINOMA;

EID: 2642648622     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.05.457489     Document Type: Review

References (24)

1. Okazaki, S., Asao, T., Wakida, M., Ishida, K., Washinosu, M., Utsugi, T., Yamada, Y. (Taiho Pharm. Co., Ltd.). Novel fused indan deriv. and pharmaceutically acceptable salt. EP 713870, US 5710162, US 5733918, WO 9532187.
2. Okazaki, S., Wakida, M., Ishida, K., Utsugi, T., Yamada, Y., Asano, T. Synthesis of novel indeno[2,1-c]quinolin-7-one derivatives and their topoisomerase inhibitory and antitumor activities. 17th Symp Med Chem/6th Annu Meet Div Med Chem/2nd Conf Drug Discov (Nov 19-21, Tsukuba) 1997, Abst 2-P-05.
3. Utsugi, T., Aoyagi, K., Aoyagi, Y., Sano, M., Wierzba, K., Okazaki, S., Asao, T., Yamada, Y. Antitumor activity of a novel quinoline derivative TAS-103. I. 55th Annu Meet Jpn Cancer Assoc (Oct 10-12, Yokohama) 1996, Abst 2372.
4. Utsugi, T., Aoyagi, K., Furune, Y., Sano, M., Wierzba, K., Okazaki, S., Asao, T., Yamada, Y. Antitumor activity of TAS-103, a novel topoisomerase I and II inhibitor. Proc Amer Assoc Cancer Res 1996, 37: Abst 2915.
5. Utsugi, T., Aoyagi, K., Asao, T., Okazaki, S., Aoyagi, Y., Sano, M., Wierzba, K., Yamada, Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997, 88: 992-1002.
6. Aoyagi, K., Utsugi, T., Kobunai, T., Nakaoka, M., Wierzba, K., Yamada, Y. Antitumor activity of a novel quinoline derivative TAS-103. IV. 56th Annu Meet Jpn Cancer Assoc (Sept 25-27, Kyoto) 1997, Abst VAP-063.
7. Utsugi, T., Kobunai, T., Aoyagi, K., Aoyagi, Y., Nakaoka, M., Yamada, Y. Antitumor activity of TAS-103, a novel topoisomerase I and II inhibitor, against orthotopically implanted human cancers. Proc Amer Assoc Cancer Res 1997, 38: Abst 2044.
8. Fujimoto, S., Aoyagi, Y., Yamada, Y. Antitumor spectrum of TAS-103 against human surgical specimens. 56th Annu Meet Jpn Cancer Assoc (Sept 25-27, Kyoto) 1997, Abst NHO-02.
9. Ishida, T., Nishio, K., Arioka, H., Kurokawa, H., Fukumoto, H., Fukuoka, K., Nomoto, T., Yokote, H., Saijo, N. TAS-103, a novel dual inhibitor of DNA topoisomerase I and II. 55th Annu Meet Jpn Cancer Assoc (Oct 10-12, Yokohama) 1996, Abst 701.
10. Ishida, T., Nishio, K., Arioka, H., Kurokawa, H., Fukumoto, H., Fukuoka, K., Nomoto, T., Yokote, H., Saijo, N. TAS-103, a novel dual inhibitor of DNA topoisomerase I and II. Proc Amer Assoc Cancer Res 1996, 37: Abst 2922.
11. Kawanami, K., Nakamura, T., Sekimizu, K., Matsuo, K., Yamada, Y., Kuwano, M. TAS-103 as both DNA topoisomerase I and II-targeting anticancer agent. I. Novel action-site(s). 55th Annu Meet Jpn Cancer Assoc (Oct 10-12, Yokohama) 1996, Abst 2374.
12. Nakamura, T., Ono, M., Furukawa, M., Wada, M., Kuwano, M., Utsugi, T., Yamada, Y. DNA conformational changes induced by the antitumor agent TAS-103 targeted to both topoisomerase I and II. Proc Amer Assoc Cancer Res 1997, 38: Abst 93.
13. Ishida, T., Nishio, K., Arioka, H. et al. Cytotoxic mechanisms of a novel DNA topoisomerase I and II dual inhibitor, TAS-103. Proc Amer Assoc Cancer Res 1996, 38: Abst 137.
14. Nakamura, T., Kawanami, K., Ono, M., Taniguchi, K., Yokomizo, A., Matsumoto, K., Yamada, Y., Kuwano, M. TAS-103 as both DNA topoisomerase I and II-targeting anticancer agent. II. Characterization of drug resistant cells. 55th Annu Met Jpn Cancer Assoc (Oct 10-12, Yokohama) 1996, Abst 2375.
15. Nakaoka, M., Utsugi, T., Kobunai, T., Yamada, Y. Mechanism of action of a novel quinoline derivative, TAS-103, inhibiting DNA topoisomerase I and II. 56th Annu Meet Jpn Cancer Assoc (Sept 25-27, Kyoto) 1997, Abst VAP-062.
16. Yano-Yanagisawa, H., Tandon, R., Samara, G.J., Close, L.G., Utsugi, T., Yamada, Y., Sato, T. Investigation of mechanism of apoptosis induced by a dual inhibitor of DNA topoisomerase I and II (TAS-103). Proc Amer Assoc Cancer Res 1997, 38: Abst 132.
17. Utsugi, T., Kobuna, T., Aoyagi, K., Aoyagi, Y., Nakaoka, M., Sano, M., Wierzba, K., Okazaki, S., Asao, T., Yamada, Y. Development of a novel quinoline derivative TAS-103 targeting topoisomerase I and II. 56th Annu Meet Jpn Cancer Assoc (Sept 25-27, Kyoto) 1997, Abst S11-03.
18. Bristol-Myers Squibb acquires broad-spectrum antitumor agents. Prous Science Daily Essentials August 11, 1997.
19. Aoyagi, Y., Utsugi, T., Aoyagi, K., Sano, M., Wierzba, K., Okazaki, S., Asao, T., Yamada, Y. Antitumor activity of a novel quinoline derivative TAS-103, inhibiting DNA topoisomerase I and II. 55th Annu Meet Jpn Cancer Assoc (Oct 10-12, Yokohama) 1996, Abst 2371.
20. Yamamoto, Y., Nagayama, S., Kawaguchi, Y., Komori, T., Kousa, T., Odagiri, Y. Pharmacokinetics study of TAS-103, a novel anticancer agent. Xenobiotic Metab Dispos 1997, 12(Suppl.): Abst P-210.
21. Azuma, R., Urakawa, A. Simultaneous determination of a novel anticancer drug, TAS-103, and its N-demethylated metabolite in monkey plasma by high-performance liquid chromatography using solid-phase extraction. J Chromatogr B 1997, 691: 179-85.
22. Aoyagi, Y., Utsugi, T., Kobunai, T., Yamada, Y. In vitro antitumor activity of a novel quinoline derivative, TAS-103, inhibiting topoisomerase I and II. Proc Amer Assoc Cancer Res 1998, 39: Abst 557.
23. Sunami, T., Nishio, K., Kanzawa, F., Fukuoka, K., Yoshikawa, J., Saijo, N. Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. Proc Amer Assoc Cancer Res 1998, 39: Abst 4056.
24. Ohyama, T., Utsugi, T., Yamada, Y., Sato, T. Investigation of mechanisms of apoptosis induced by a dual inhibitor of DNA topoisomerase I and II (TAS-103). Proc Amer Assoc Cancer Res 1998, 39: Abst 3597.